ABYSS Trial: No Difference in Outcomes Continuing or Stopping Beta-Blockers Following MI

The ABYSS trial suggests continuing beta-blockers may not be necessary for post-MI patients with preserved ejection fraction, but further research is needed. Results showed no safety preservation or quality of life benefits with beta-blocker interruption, with similar rates of death, MI, and stroke between groups, but higher rates of cardiovascular hospitalizations in the interruption group.


Related News

ABYSS Trial: No Difference in Outcomes Continuing or Stopping Beta-Blockers Following MI

The ABYSS trial suggests continuing beta-blockers may not be necessary for post-MI patients with preserved ejection fraction, but further research is needed. Results showed no safety preservation or quality of life benefits with beta-blocker interruption, with similar rates of death, MI, and stroke between groups, but higher rates of cardiovascular hospitalizations in the interruption group.

© Copyright 2024. All Rights Reserved by MedPath